<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8087A3C3-09A8-4495-8205-03AF95BFFB0E"><gtr:id>8087A3C3-09A8-4495-8205-03AF95BFFB0E</gtr:id><gtr:firstName>Jean</gtr:firstName><gtr:surname>Manson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FA%2F00001665"><gtr:id>28168F89-B10B-4EB7-BDF2-8C29109EBB3A</gtr:id><gtr:title>The Role of Prp in Alzheimers Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/A/00001665</gtr:grantReference><gtr:abstractText>Both the amyloid precursor protein (APP) and and PrPC are subject to proteolytic cleavage by the same zinc metalloproteases. We therefore tested the involvement of PrPC in the proteolytic processing of APP and showed the cellular production of the neurotoxic Abeta is regulated by PrPC. We now aim to examine whether this finding has implications for both Alzheimers and prion diseases. The following will be addressed: Does a decrease in PrP expression increase the progression of AD? Does A? contribute to the neurodegeneration seen in prion disease? Do A? levels alter over time in PrP knockout vs wild type mice? Do A? levels increase during the course of prion infection? Do mutations in PrP that give rise to spontaneous prion disease (e.g. P101L) increase the levels of A? in the brain.</gtr:abstractText><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>55400</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Lack of the prion protein in the presence of human APP produces alterations in specific behavioural tasks associated with hippocampal function and pathological findings in the hipocampal region of the brain.</gtr:description><gtr:exploitationPathways>The production of an appropriate model of AD is essential to study aspects of onset, progressing and intervention in AD . The pilot project has allowed us to produce a pontential model and has indicated phenotypes which need to be assessed in aging animals before the value of this model can be fully assessed.</gtr:exploitationPathways><gtr:id>FB9461DB-3CE7-404E-A2D5-ED58A8F56BD4</gtr:id><gtr:outcomeId>56c1dd5ca4a342.70548491</gtr:outcomeId><gtr:sectors><gtr:sector>Other</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the International Science Advisory Council of APRI</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>48C65BDA-227C-4DD5-910C-844418052C7A</gtr:id><gtr:impact>The importance of this committee which I now chair is to provide scientific knowledge and expertise to the growing scientific community of the APRI</gtr:impact><gtr:outcomeId>ZWNVcPTjyBh</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the UK SEAC Advisory Body</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F93E2E46-0772-480C-869A-2E5429385F83</gtr:id><gtr:impact>Spongiform Encephalopathy Advisory Committee advised Government on all accept of the Transmissible Spongiform Encephalopathies throughout the BSE and vCJD epidemics</gtr:impact><gtr:outcomeId>RriG7TJeFFs</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the European Food Safety Authority</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>221B4F78-0C61-46FE-B606-B0EDDD5E57A2</gtr:id><gtr:impact>involved in development of policy on prion diseases</gtr:impact><gtr:outcomeId>tLEj8xgWTLE</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the British Neuroscience Advisory Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BAAC0316-CDC2-4135-B8B9-E007F97C46E7</gtr:id><gtr:outcomeId>pz9cTFBTzRy</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO TSE Working Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1713FC69-09ED-4B9A-8D16-360DE056D5BF</gtr:id><gtr:impact>developed policy on prion diseases</gtr:impact><gtr:outcomeId>qwPK2twTjcL</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the ACDP</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4078A3FE-73C1-49A1-ABA5-4F3F6CF9244C</gtr:id><gtr:impact>The Advisory Committee on Dangerous pathogens advises the UK government on all issues related to dangerous pathogens from situations, in the field, in health care and laboratory practice. I serve on the committee as the expert on the Transmissible Spongiform Encephalopathies</gtr:impact><gtr:outcomeId>bvz7Yv6fNjU</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the CJD Sample Oversight Committee Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>069E9CA5-4537-4142-B35C-607FF2504C30</gtr:id><gtr:impact>The committee aims to facilitate the development of diagnostics for vCJD through working with developers and providing access to rare samples</gtr:impact><gtr:outcomeId>rkpScXXqDHh</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>37AEB840-D1D1-449D-AA29-8F34B6491AAD</gtr:id><gtr:title>Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-? or Pathologic Phenotype.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e48e96d9bf224f83e6404d9aaaff3f"><gtr:id>18e48e96d9bf224f83e6404d9aaaff3f</gtr:id><gtr:otherNames>Whitehouse IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58bd4185369693.24483532</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/A/00001665</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>